PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :
C12Q 1/70, 1/68, C07H 21/04
A61K 48/00, G01N 33/53

A1

(11) International Publication Number: WO 91/08313

(43) International Publication Date: 13 June 1991 (13.06.91)

(21) International Application Number: PCT/US90/07067

(22) International Filing Date: 3 December 1990 (03.12.90)

(30) Priority data:
445,196 4 December 1989 (04.12.89) US

(60) Parent Application or Grant
(63) Related by Continuation
US 445,196 (CIP)
Filed on 4 December 1989 (04.12.89)

(71) Applicant *(for all designated States except US)*: ISIS PHARMACEUTICALS, INC. [US/US]; 2280 Faraday Avenue, Carlsbad, CA 92008 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)* : CROOKE, Stanley, T. [US/US]; 3211 Piragua Street, Carlsbad, CA 92009 (US). MIRABELLI, Christopher, K. [US/US]; 1728 Shadow Mountain Drive, Encinitas, CA 92024 (US). ECKER, David, J. [US/US]; 2609 Colibri Lane, Carlsbad, CA 92009 (US). COWSERT, Lex, M. [US/US]; 3550 Simsbury Court, Carlsbad, CA 92008 (US).

(74) Agents: CALDWELL, John, C. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris, One Liberty Place - 46th Floor, Philadelphia, PA 19103 (US).

(81) Designated States: AT (European patent), AU, BE (European patent), BR, CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), US.

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ANTISENSE OLIGONUCLEOTIDE INHIBITION OF PAPILLOMAVIRUS

(57) Abstract

Oligonucleotides and oligonucleotide analogs are provided which are capable of antisense interaction with messenger RNA of papillomavirus. Such oligonucleotides or oligonucleotide analogs can be used for diagnostics and therapeutics as well as for research purposes. In accordance with preferred embodiments of this invention, oligonucleotide or oligonucleotide analog is provided which is hybridizable with a messenger RNA from a papillomavirus. The oligonucleotide or oligonucleotide analog is able to inhibit the function of the RNA, and accordingly is useful for therapy for infections by such papillomavirus. In accordance with a preferred embodiment, portions of the papillomavirus are targeted for antisense attack. Thus oligonucleotides are preferably provided which hybridize with the E2, E1, E7, or E6-7 messenger RNAs.

ANTISENSE OLIGONUCLEOTIDE INHIBITION OF PAPILLOMAVIRUS

FIELD OF THE INVENTION

This invention relates to the inhibition of papillomavirus and the diagnosis and treatment of infections in animals caused by papillomavirus. This invention is also directed to the detection and quantitation of papillomavirus in samples suspected of containing it. Additionally, this invention is directed to oligonucleotides and oligonucleotide analogs which interfere with or modulate the function of messenger RNA from papillomavirus. Such interference can be employed as a means of diagnosis and treatment of papillomavirus infections. It can also form the basis for research reagents and for kits both for research and for diagnosis. This is a continuation-in-part application of U.S. Serial No. 445,196 filed December 4, 1989, entitled "Antisense Oligonucleotide Inhibition of Papillomavirus".

BACKGROUND OF THE INVENTION

The papillomaviruses (PV) are widespread in nature and are generally associated with benign epithelial and fibroepithelial lesions commonly referred to as warts. They have been detected in and isolated from a variety of higher vertebrates including human, cattle, rabbits, deer and several avian species. Although these viruses are generally associated with benign lesions, a specific subset of the viruses have been associated with lesions that may progress to carcinomas. The implication that these viruses may play a etiologic role in the development of some human cancers follows from numerous studies that have shown the presence of

transcriptionally active human papillomavirus (HPV) deoxyribonucleic acids in a high percentage of certain cancerous lesions. Zur Hausen, H. and Schneider, A. 1987. In: The Papovaviridae, vol. 2, edited by N. P. Salzman and P. M. Howley, pp. 245-264. Plenum Press, New York.

In man, human papillomaviruses cause a variety of disease including common warts of the hands and feet, laryngeal warts and genital warts. More than 57 types of HPV have been identified so far. Each HPV type has a preferred anatomical site of infection; each virus can generally be associated with a specific lesion. Genital warts, also referred to as venereal warts and condylomata acuminata, are one of the most serious manifestations of PV infection. As reported by the Center for Disease Control, the sexual mode of transmission of genital warts is well established and the incidence of genital warts is on the increase. The seriousness of genital warts is underlined by the recent discovery that HPV DNA can be found in all grades of cervical intraepithelial neoplasia (CIN I-III) and that a specific subset of HPV types can be found in carcinoma *in situ* of the cervix. Consequently, women with genital warts, containing specific HPV types are now considered at high risk for the development of cervical cancer. Current treatments for genital warts are inadequate.

There is a great, but as yet unfulfilled, desire to provide compositions of matter which can interfere with papillomavirus. It is similarly desired to achieve methods of therapeutics and diagnostics for papillomavirus infections in animals. Additionally, improved kits and research reagents for use in the study of papillomavirus are needed.

OBJECTS OF THE INVENTION

It is an object of this invention to provide oligonucleotides and oligonucleotide analogs which are capable of hybridizing with messenger RNA of papillomavirus to inhibit the function of the messenger RNA.

It is a further object to provide oligonucleotides

and analogs which can modulate the functional expression of papillomavirus DNA through antisense interaction with messenger RNA of the virus.

Yet another object of this invention is to provide methods of diagnostics and therapeutics for papillomavirus in animals.

Methods, materials and kits for detecting the presence or absence of papillomavirus in a sample suspected of containing it are further objects of the invention.

Novel oligonucleotides and oligonucleotide analogs are other objects of the invention.

These and other objects will become apparent to persons of ordinary skill in the art from a review of the instant specification and appended claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic map of the genetic organization of several PV genomes.

Figure 2 is a partial genetic mapping of a bovine papillomavirus, BPV-1, genome showing open reading frames, ORFs, and messenger RNAs transcribed from the genome.

Figure 3 is a nucleotide sequence of the BPV-1 E2 transactivator gene mRNA showing nucleotides 2443 through 4203.

Figure 4 is a nucleotide sequence of the BPV-1 E2 transactivator gene mRNA showing the domain having nucleotides 2443 through 3080.

Figure 5 is a nucleotide sequence of the 5' common untranslated region of BPV-1 coding for early messenger RNAs showing the domain having nucleotides 89 through 304.

Figure 6 is the nucleotide sequences of antisense oligonucleotides made in accordance with the teachings of the invention and the relative position of the oligonucleotides on the E2 mRNA. The oligonucleotide identifier, sequence and functional role are depicted.

Figure 7 is a graphical depiction of the effects of antisense oligonucleotides made in accordance with the

teachings of the invention on E2 expression. Oligonucleotides targeted to the mRNA CAP region (I1751) and the translation codon for the E2 transactivator (I1753) are shown to reduce E2 transactivation at micromolar concentrations.

Figure 8 is a graphical depiction of the dose response of antisense oligonucleotides made in accordance with the teachings of the invention.

These dose response curves show that an antisense oligonucleotide, I1753, which is complementary to the E2 transactivation messenger RNA in the region including the translation initiation codon has an 50% inhibitory concentration (IC_{50}) in the range of 50-100 nM while an oligonucleotide targeted to the CAP region of the same message (I1751) has an IC_{50} in the range of 500 nM.

Figure 9 is the nucleotide sequences of antisense oligonucleotides made in accordance with the teachings of the invention targeted to the transactivator and transrepressor regions of the E2 mRNA.

Figure 10 is a graphical depiction of the effects of selected oligonucleotides targeted to the transactivator region of the E2 mRNA. The 15 to 20 mer antisense oligonucleotides made in accordance with the teachings of the invention are shown to inhibit E2 transactivation.

Figure 11 is a graphical depiction of the effects of selected oligonucleotides targeted to the transrepressor region of the E2 mRNA. The 15 to 20 mer antisense oligonucleotides made in accordance with the teachings of the invention are shown to inhibit E2 transrepression.

Figure 12 is a photographic depiction of the consequences of reduction of E2 transactivator *in situ* on the biology of BPV-1. Antisense oligonucleotides made in accordance with the teachings of the invention were tested for the ability to inhibit or attenuate BPV-1 transformation of C127 cells. The photograph depicts petri dishes plated with test cells.

Figure 13 is a graphical depiction of the effects of selected oligonucleotides targeted to the transactivator

region of the E2 mRNA. The inhibition of BPV-1 focus formation by antisense oligonucleotides made in accordance with the teachings of the invention is depicted. These dose response curves for I1751 and I1753 show that I1753 had an IC_{50} in the range of 10 nM while I1751 had an IC_{50} in the range of 100 nM.

Figure 14 is a graphical depiction of the effects of antisense oligonucleotides made in accordance with the teachings of the present invention on the ability of BPV-1 to replicate its genome. Cells transformed by the virus were treated with I1753 and I1751 and the viral DNA quantitated.

Figure 15 shows the results of immunoprecipitation assays wherein metabolically labelled oligonucleotide-treated cells or untreated controls were immunoprecipitated using a monoclonal antibody.

Figure 16 is the nucleotide sequence of HPV-11 in the region of the translation initiation codon of E2.

SUMMARY OF THE INVENTION

In accordance with preferred embodiments of this invention, oligonucleotides and oligonucleotide analogs are provided which are hybridizable with messenger RNA from papillomavirus. This relationship is commonly denominated as "antisense." The oligonucleotides and oligonucleotide analogs are able to inhibit the function of the RNA, either its translation into protein, its translocation into the cytoplasm, or any other activity necessary to its overall biological function. The failure of the messenger RNA to perform all or part of its function results in failure of the papillomavirus genome to be properly expressed; multiplication fails, correct progeny are not formed in effective numbers, and the deleterious effects of those progeny upon animals infected with the papillomavirus are modulated.

It has now been found to be preferred to target portions of the papillomavirus genome, as represented by certain of its mRNAs,for antisense attack. It has now been discovered that the E2, E1, E7 and E6-7 mRNAs of

papillomaviruses are particularly suitable for this approach. Thus, it is preferred that the messenger RNA with which hybridization by the oligonucleotide or oligonucleotide analog is desired, be messenger RNAs E2, E1, E7, or E6-7. In accordance with still more preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which comprise nucleotide base sequences designed to be complementary with RNA portions transcribed from the E2 transactivator region or the 5' common untranslated region of the papillomavirus as exemplified, in bovine papillomavirus-1, by nucleotides 2443 through 3080 or 89 through 304.

In the most preferred embodiment, oligonucleotides are provided which are targeted to the mRNA CAP region and the translation codon for the E2 transactivator. These oligonucleotides are designed to hybridize with E2 mRNA encoded by BPV-1 nucleotides 2443 through 4180.

Methods of modulating the expression of papillomavirus have now been discovered comprising contacting messenger RNA from said papillomavirus with an oligonucleotide or oligonucleotide analog hybridizable with a messenger RNA from the papillomavirus, which oligonucleotide or oligonucleotide analog inhibits the function of said messenger RNA when hybridized therewith. Employment of oligonucleotides or oligonucleotide analogs which are designed to hybridize with the E2, E1, E7, or E6-7 mRNAs of papillomavirus are preferred.

Additionally, methods of modulating the effects of a papillomavirus infection in an animal have now been discovered comprising contacting the animal with an oligonucleotide or oligonucleotide analog hybridizable with a messenger RNA from a papillomavirus, that inhibits the function of said messenger RNA when hybridized therewith. Oligonucleotide or oligonucleotide analog hybridizable with E2, E1, E7, or E6-7 mRNAs of papillomavirus are preferred.

Diagnostics for detecting the presence or absence of papillomavirus employing such oligonucleotides or oligonucleotide analogs are also within this invention as are

kits for such diagnostic activity and research reagents depending upon such hybridization.

DETAILED DESCRIPTION OF THE INVENTION

Genital warts are the most frequently diagnosed, viral, sexually transmitted disease. Clinically, they may be categorized into two major groups: condyloma acuminata and flat cervical warts. Condylomas have been shown to contain virus particles and molecular studies have demonstrated that greater than 90% of these lesions contain either HPV-6 or HPV-11 DNA. Gissmann, L., Wolnik, L., Ikenberg, H., Koldovsky, U., Schnurch, H.G. & zur Hausen, H. Proc. Natl. Acad. Sci. USA **80**, 560-563 (1983). Condyloma acuminata generally occur on the penis, vulva or in the perianal region. They may spontaneously regress or persist for years and progression to an invasive carcinoma occurs only at a low frequency. Unlike other genital warts, those occurring on the uterine cervix usually exhibit a flat rather than acuminate morphology, and are usually clinically detected by Pap smear. A papillomavirus etiology for cervical dysplasia was suggested by the studies of cytologists in the late 1970s who demonstrated the association on Pap smear of cytologic changes due to HPV infection with those of dysplasia. Other studies showed the presence of viral particles and viral capsid antigen in some of the dysplastic cells of these lesions. This association was important because previous clinical studies had established that cervical dysplasia (also referred to as CIN, or cervical intra-epithelial neoplasia) was a precursor to carcinoma *in situ* which was in turn recognized to be a precursor to invasive squamous epithelial cell carcinoma of the cervix. HPV-types 16 and 18 were cloned out directly from cervical carcinoma. Dürst, M., Gissmann, L., Ikenberg, H. & zur Hausen, H., Proc. Natl. Acad. Sci. USA **80**, 3812-3815 (1983); Boshart, M., Gissmann, L., Ikenberg, H., Kleinheinz, A., Scheurlen, W. & zur Hausen, H., EMBO J. **3**, 1151-1157 (1984). These were subsequently used as hybridization probes to show that greater than 70% of the human cervical carcinomas

and the derived cell lines scored positive for the presence of either of these HPV types. Another 20% contain additional HPV-types such as HPV-31, HPV-33, and HPV-35.

Data collected from the National Therapeutic Index showed that in 1984 there were 224,900 first office visits for genital warts and 156,720 first office visits for genital herpes. The incidence of genital warts has steadily increased throughout the 1970s and 1980s, as was recently demonstrated by an epidemiological study in which the mean incidence from 1950 to 1978 reached a peak of 106.5 per 100,000 population. The prevalence of cervical HPV infection in women aged 25 to 55 proved to be 0.8%, but in 22 year old women it was 2.7%. Recent studies on cytologically normal women have demonstrated the incidence of latent infection to be 11%. Thus, there appears to be a latent stage of the disease which suggest an even greater incidence and prevalence.

Active genital warts can be identified in approximately 2.5% of pregnant American women, thus being implicated in 60,000 to 90,000 pregnancies annually. HPV infections are more than twice as prevalent in pregnant women. Each year there are an estimated 1,500 new cases of laryngeal papillomatosis, indicating that the risk of infection from mother to newborn is 1:80 to 1:200.

Laryngeal papillomas are benign epithelial tumors of the larynx. Two PV types, HPV-6 and HPV-11, are most commonly associated with laryngeal papillomas. Clinically, laryngeal papillomas are divided into two groups, juvenile onset and adult onset. In juvenile onset it is thought that the neonate is infected at the time of passage through the birth canal of a mother with a genital PV infection. Disease is usually manifest by age 2 and is characterized by the slow but steady growth of benign papillomas that will ultimately occlude the airway without surgical intervention. These children will typically undergo multiple surgeries with the papillomas always reoccurring. Patients will ultimately succumb to complications of multiple surgery. To date there is no curative treatment for juvenile onset laryngeal

papillomatosis and spontaneous regression is rare. Adult onset laryngeal papillomatosis is not as aggressive and will frequently undergo spontaneous remission.

The most common disease associated with papillomavirus infection are benign skin warts. Common warts generally contain HPV types 1, 2, 3, 4 or 10. These warts typically occur on the soles of feet, plantar warts, or on the hands. Common skin warts are most often found in children and young adults. Later in life the incidence of common warts decreases presumably due to immunologic and physiologic changes. Plantar warts can often be debilitating and require surgical removal and they frequently reoccur after surgery. To date there is no reliable treatment for plantar warts. Common warts of the hands are unsightly but rarely become debilitating and are therefore not usually surgically treated.

Epidermodysplasia verruciformis (EV) is a rare genetically transmitted disease which is characterized by disseminated flat warts that appear as small reddish macules. A variety of HPV types have been associated with EV. With time approximately one third of EV patients develop squamous cell carcinoma (SCC) of the skin at multiple sites. In general, SCC occurs on sun exposed areas of the skin. Only a subset of EV associated PV is consistently found in SCC, HPV-5 and HPV-8. Genetic predisposition, immunologic abnormalities, and UV irradiation as well as HPV may all contribute to the development of SCC in these patients.

The PV genome consists of a double stranded, covalently closed, circular DNA molecule of approximately 8,000 base pairs. The complete nucleotide sequence and genetic organization of a number of animal and human PVs have been determined including bovine papillomavirus type 1 (BPV-1). Chen, E.Y., Howley, P.M., Levinson, A.D. & Seeburg, P.H., Nature **299**, 529-534 (1982). Schematic maps of several PV genomes are shown in Figure 1. Viral transcription is unidirectional: all viral mRNAs are transcribed from the same strand of viral DNA. Engel, L.W., Heilman, C.A. & Howley, P.M., J. Virol. **47**, 516-528 (1983); Heilman, C.A., Engel, L.,

Lowy, D.R. & Howley, P.M., Virology 119, 22-34 (1982). The coding strand contains 10 designated open reading frames (ORFs). The individual ORFs have been classified as either "early" or "late" ORFs based on their position in the PV genome and their pattern of expression in non-productively versus productively infected cells. Figure 2 depicts the relationships of several ORFs for bovine papillomavirus-1.

Because of its ability to transform rodent cells and maintain its genome as an episome in transformed cells, BPV-1 has served as the model papillomavirus in *vitro* studies. As a result, BPV-1 is the best characterized of all the papillomaviruses. The BPV-1 genome is 7946 base pairs in length and has been cloned and sequenced. Chen *et al.*, 1982, supra. DNA sequence analysis of BPV-1 has defined 8 early (E) and 2 late (L) open reading frames (ORFs). Designation of ORFs as early or late was based on their pattern of expression in nonproductively infected transformed cells versus permissively infected cells. Heilman *et al.*, 1982, supra; Baker, C.C. & Howley, P.M. EMBO J. 6, 1027-1035 (1987).

All ORFs are contained on the same stand of DNA and all mRNAs currently characterized have been shown to be transcribed from the coding strand. Amtmann, E. & Sauer, G., J. Virol. 43, 59-66 (1982). The functions of the BPV-1 ORFs have been analyzed by recombinant DNA techniques and *in vitro* cell culture systems. Several ORFs have been shown to have multiple functions. The E5 and E6 ORFs have been shown to encode transforming proteins. Yang, Y.C., Okayama, H. & Howley, P.M., Proc. Natl. Acad. Sci. USA 82, 1030-1034 (1985). The E1 and E7 ORFs are involved in maintenance of high copy number of the BPV-1 genome within the infected cell. Lusky, M. & Botchan, M.R., J. Virol. 53, 955-965 (1985).

The 3' E1 ORF encodes a factor required for viral genome replication and maintenance of the viral genome. Lusky, M. & Botchan, M.R., J. Virol. 60, 729-742 (1986). The 5' E1 ORF encodes a modular of viral DNA replication. Roberts, J.M. & Weintraub, H., Cell 46, 741-752 (1986). The full length E2 ORF encodes a protein which transactivate viral

transcription, (Spalholz, B.A., Yang, Y.C. & Howley, P.M., Cell 42, 183-191 (1985)) while the 3' E2 ORF encodes a transrepressor of viral transcription. Lambert, P.F., Spalholz, B.A. & Howley, P.M., Cell 50, 69-78 (1987). No functions for E3, E4, and E8 of BPV-1 have yet been defined.

L1 (Cowsert, L.M., Pilacinski, W.P. & Jenson, A.B., Virology 165, 613-615 (1988)) and L2 encode capsid proteins.

In accordance with this invention, persons of ordinary skill in the art will understand that messenger RNA identified by the open reading frames of the DNA from which they are transcribed include not only the information from the ORFs of the DNA, but also associated ribonucleotides which form regions known to such persons as the 5' cap region, the 5' untranslated region, and 3' untranslated region. Thus, oligonucleotide and oligonucleotide analogs may be formulated in accordance with this invention which are targeted wholly or in part to these associated ribonucleotides as well as to the informational ribonucleotides.

Within the BPV-1 genome a region of about 1,000 base pairs in length, located between 7,094 and 48 has been identified that has no extensive coding potential. This region is referred to as the long control region (LCR). The LCR contains multiple CIS control elements that are critical for the regulation of viral transcription and viral replication. A summary of functional assignments for the ORFs is set forth in Table 1.

Transcription of the BPV-1 genome is complicated by the presence of multiple promoters and complex and alterative splice patterns. Eighteen different mRNA species have been identified so far by a variety of methods. Amtmann, E. & Sauer, G., J.Virol. 43, 59-66 (1982); Burnett, S., Moreno-Lopez, J. & Pettersson, U., Nucleic Acids Res. 15, 8607-8620 (1987); Engel, L.W., Heilman, C.A. & Howley, P.M., J.Virol. 47, 516-528 (1983); Heilman, C.A., Engel, L., Lowy, D.R. & Howley, P.M., Virology 119, 22-34 (1982); Baker, C.C. & Howley, P.M., EMBO J. 6, 1027-1035 (1987); Stenlund, A., Zabielski, J., Ahola, H., Moreno-Lopez, J. & Pettersson, U.,

J.Mol.Biol. 182, 541-554 (1985); and Yang, Y.C., Okayama, H. & Howley, P.M., Proc. Natl. Acad. Sci. USA 82, 1030-1034 (1985).

All early mRNAs appear to use a common polyadenylation signal at nucleotide (nt) 4180 which is positioned down stream of the early ORFs, while late mRNAs use a second polyadenylation signal at nt 7156. Sequence analysis of BPV-1 cDNAs revealed the presence of multiple 5' splice sites (at nt 304, 864, 1234, 2505, 3764, and 7385) and 3' splice sites (at nt 528, 3225, 3605, 5609) resulting in alternative splicing events. The 5' end of most BPV-1 mRNAS map to nt 89 and contain a common region between nt 89 and the first splice donor site at nt 304. The 5' end of other mRNAs map to nts 890, 2443 and 3080.

It is to be expected that differences in the DNA of papillomaviruses from different species and from different types within a species exist. It is presently believed, however, that the similarities among the ORFs of the various PVs as the same might effect the embodiment of the present invention, outweigh the differences. Thus, it is believed, for example, that the E2 regions of the various PVs serve essentially the same function for the respective PVs and that interference with expression of the E2 genetic information will afford similar results in the various species. This is believed to be so even though differences in the nucleotide sequences among the PV species doubtless exist.

Accordingly, nucleotide sequences set forth in the present specification will be understood to be representational for the particular species being described. Homologous or analogous sequences for different species of papillomavirus are specifically contemplated as being within the scope of this invention.

Early genetic experiments showed that deletion or mutation of E2 resulted in loss of BPV focus forming activity on C127 cells suggesting a transforming function for E2. Later studies showed that E2 was a regulator of viral transcription and that loss of transforming ability by

mutation of E2 was due to the down regulation of other transforming genes through E2 conditional enhances. The full length E2 ORF encodes the E2 transactivator which stimulates transcription of viral early genes. The E2 transactivator is translated from an unspliced mRNA whose 5'end maps to nt 2443 as shown as species N in Figure 2. The E2 transrepressor is an N-terminally truncated form of the E2 transactivator, generated by initiation of transcription within the E2 ORF by a promoter at nt 3089. Species O, Figure 2. The transactivating (5' portion) and DNA binding domains (3' portion) as well as the palindromic DNA recognition sequence (ACCN6GGT) of E2 have been identified. Both E2 mRNA and protein have been shown to have a very short half life, on the order of less than about 60 minutes. The E2 transregulatory circuit is a general feature among papilloma viruses. E2 transregulator has been documented in every papillomavirus examined to date.

The PV genome is packaged in a naked icosahedral capsid 55 nm in diameter. The viral capsid in nonenveloped and is not glycosylated. Two viral encoded proteins, designated L1 and L2, make up the capsid. L1 is the major capsid protein, constitutes 80% of the protein present in the virion, and has a molecular weight ranging between 50 to 60 kD. The L2 is a minor capsid protein with a theoretical molecular weight of 51 kD but has been shown to migrate at 76 kD. Because PV cannot be produced *in vitro* and very few mature virions are found in productive lesions it has not been possible to do a detailed study of the serology of PV.

The papillomavirus life cycle is complex and poorly understood at this time. To date no *in vitro* system that allows production of mature PV virions has been developed as a result it has not been possible to characterize the life cycle of papillomaviruses. PV have a restricted host range rarely crossing species barriers. In addition PV infect only differentiating epithelium, either mucosal or keratinizing. Regulation of the PV gene expression is thought to be intimately linked to the differentiation program of host

epithelial cells. The currently favored model of the PV life cycle is as follows: infectious PV particles penetrate the outer layers of the epithelium via trauma and infect the basal cells of host tissue. There the virus is maintained as a relatively low copy extrachromosomal element. As the epithelial cells begin to undergo differentiation, the PV genome is replicated to high copy number, as the cells begin to undergo the terminal stages of differentiation late genes are expressed and the viral genome is encapsulated.

Papillomavirus has been discovered to be an ideal target for antisense therapy. First, papillomavirus lesions are external, allowing topical approaches to delivery of antisense oligonucleotides and eliminating many of the problems such as rapid clearance, and obtaining clinically active tissue concentrations of oligonucleotides associated with systemic administration of synthetic oligonucleotides. Second, the viral genome is maintained in the infected cell as a separate genetic element. This opens the door to the possibility of curative therapy, as opposed to treatment of symptoms, by attacking replication functions of the virus.

It has been discovered that the E2 ORF on papillomavirus genomes is particularly well-suited for antisense oligonucleotide design. E2 has been shown to be the major transactivator of viral transcription in both BPV-1 and HPV systems. Mutations in the E2 ORF have pleiotropic effects on transformation and extrachromosomal DNA replication. DiMaio, D., J.Virol. **57**, 475-480 (1986); DiMaio, D. & Settleman, J., EMBO J. **7**, 1197-1204 (1988); Groff, D.E. & Lancaster, W.D., Virology **150**, 221-230 (1986); Rabson, M.S., Yee, C., Yang, Y.C. & Howley, P.M., J.Virol. **60**, 626-634 (1986); and Sarver, N., Rabson, M.S., Yang, Y.C., Byrne, J.C. & Howley, P.M., J.Virol. **52**, 377-388 (1984). Subsequently the E2 ORF has been shown to encode a transcriptional transactivator. Spalholz, B.A., Yang, Y.C. & Howley, P.M., Cell **42**, 183-191 (1985). A truncated version of E2 created by initiation of translation at an internal AUG has been shown to be a transrepressor of transcription. Lambert, P.F.,

Spalholz, B.A. & Howley, P.M., Cell 50, 69-78 (1987). Both the DNA binding domain, the carboxy terminal 100 amino acids, (McBride, A.A., Schlegel, R. & Howley, P.M., EMBO J. 7, 533-539 (1988)) and the DNA recognition sequence, ACCN6GGT, (Androphy, E.J., Lowy, D.R. & Schiller, J.T., Nature 325, 70-73 (1987), and Moskaluk, C. & Bastia, D., Proc.Natl.Acad.Sci.USA 84, 1215-1218 (1987)) have been identified. The E2 transcriptional regulatory circuit is a general feature among papillomaviruses. E2 transregulation has been documented in each of the other papillomaviruses examined to date. Gius, D., Grossman, S., Bedell, M.A. & Laimins, L.A., J.Virol. 62, 665-672 (1988); Hirochika, H., Broker, T.R. & Chow, L.T., J.Virol. 61, 2599-2606 (1987); Chin, M.T., Hirochika, R., Hirochika, H., Broker, T.R. & Chow, L.T., J.Virol. 62, 2994-3002 (1988); Phelps, W.C. & Howley, P.M., J.Virol. 61, 1630-1638 (1987); and Thierry, F. & Yaniv, M., EMBO J. 6, 3391-3397 (1987).

The inventors have determined that the identification of an obligatory viral transcription element that is shared among animal and human papillomaviruses causes E2 to be a prime target for an antisense approach towards papillomavirus research, diagnosis and therapy.

The inventors have determined that the E1 locus is also promising as a situs for attack upon papillomavirus. Initial mutational analysis of BPV-1 transformation of rodent fibroblast has identified the E1 as a candidate regulator of viral DNA replication. The 3' E1 ORF encodes a factor required for viral genome replication and maintenance. Sarver, N., Rabson, M.S., Yang, Y.C., Byrne, J.C. & Howley, P.M., J.Virol. 52, 377-388 (1984); Lusky, M. & Botchan, M.R., J.Virol. 53, 955-965 (1985); and Lusky, M. & Botchan, M.R., J.Virol. 60, 729-742 (1986). Inhibition of expression of E1 transcription is believed to be likely to inhibit the ability of BPV-1 (and potentially HPV) to replicate their DNA in infected cells.

The inventors have also determined that the E7 site will likely provide a further entré to therapeutics,

diagnostics and research into papillomavirus. In BPV-1, E7 has been shown to be involved in regulation of viral DNA replication. Berg, L.J., Singh, K. & Botchan, M., Mol.Cell.Biol. 6, 859-869 (1986). In HPV-16, E7 has been demonstrated to be involved in transformation and immortalization. It is not clear at this time if the E7 of HPVs are involved in replication of viral DNA, however, it is believed that E7 specific antisense oligonucleotides and analogs will inhibit replication of BPV-1 viral DNA.

The E6-E7 region of HPV has been found to be the transforming region. The exact role of this region in the life cycle of the virus is unknown at this time. However, since this region plays a central in the biology of virally induced lesions antisense it has been determined that oligonucleotides targeted to this region are likely to be useful for the purposes of this invention as well.

Recent studies have suggest that antisense oligonucleotides directed towards the 5' regions of mRNAs and preferably the cap region and the start codon are most effective in inhibiting gene expression. One feature of papillomavirus transcription is that many of the mRNAs have a common 5' untranslated region and cap. Thus it has been determined that antisense oligonucleotides directed towards this region have the potential to incapacitate more than one mRNA. The shutting down of multiple viral genes will likely act at a minimum in an additive fashion and possibly synergistically in the eradication of the viral genome from the infected cell.

It will be appreciated that the ORFs of the papillomavirus genome which give rise to the mRNAs which are preferred targets for antisense attack in accordance with the practice of certain preferred embodiments of this invention also encode portions of other mRNAs as well.

The foregoing ORFs are summarized in Table 1.

TABLE 1

Papillomavirus Open Reading Frames and their assigned Functions

ORF	ASSIGNED FUNCTIONS
E (BPV-1)	(3'portion) Replication (BPV-1)
E2(full length)	Transcriptional transactivation (BPV-1, HPV-6, HPV-16)
3' portion)	Transcriptional repression (BPV-1)
E4	Cytoplasmic phosphoprotein in warts (HPV-1)
E5	Transformation, Stimulation of DNA synthesis (BPV-1)
E6	Transformation (BPV-1)
E7	Plasmid copy number control (BPV-1)
L1	Major capsid protein
L2	Minor capsid protein

The present invention employs oligonucleotides and oligonucleotide analogs for use in antisense inhibition of the function of messenger RNAs of papillomavirus. In the context of this invention, the term "oligonucleotide" refers to a polynucleotide formed from naturally-occurring bases and cyclofuranosyl groups joined by native phosphodiester bonds. This term effectively refers to naturally-occurring species or synthetic species formed from naturally-occurring subunits or their close homologs.

"Oligonucleotide analog," as that term is used in connection with this invention, refers to moieties which function similarly to oligonucleotides but which have non naturally-occurring portions and which are not closely homologous. Thus, oligonucleotide analogs may have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur containing species

which are known for use in the art. In accordance with some preferred embodiments, at least some of the phosphodiester bonds of the oligonucleotide have been substituted with a structure which functions to enhance the ability of the compositions to penetrate into the region of cells where the RNA whose activity is to be modulated is located. It is preferred that such substitutions comprise phosphorothioate bonds, methyl phosphothioate bonds, or short chain alkyl or cycloalkyl structures. In accordance with other preferred embodiments, the phosphodiester bonds are substituted with structures which are, at once, substantially non-ionic and non-chiral. Persons of ordinary skill in the art will be able to select other linkages for use in the practice of the invention.

Oligonucleotide analogs may also include species which include at least some modified base forms. Thus, purines and pyrimidines other than those normally found in nature may be so employed. Similarly, modifications on the cyclofuranose portions of the nucleotide subunits may also occur as long as the essential tenets of this invention are adhered to.

Such analogs are best described as being functionally interchangeable with natural oligonucleotides (or synthesized oligonucleotides along natural lines), but which have one or more differences from natural structure. All such analogs are comprehended by this invention so long as they function effectively to hybridize with messenger RNA of papillomavirus to inhibit the function of that RNA.

The oligonucleotides and oligonucleotide analogs in accordance with this invention preferably comprise from about 3 to about 50 subunits. It is more preferred that such oligonucleotides and analogs comprise from about 8 to about 25 subunits and still more preferred to have from about 12 to about 20 subunits. As will be appreciated, a subunit is a base and sugar combination (or analog) suitably bound to adjacent subunits through phosphodiester or other bonds.

The oligonucleotides and oligonucleotide analogs of this invention are designed to be hybridizable with messenger

RNA of papillomavirus. Such hybridization, when accomplished, interferes with the normal function of the messenger RNA to cause a loss of its utility to the virus. The functions of messenger RNA to be interfered with include all vital functions such as translocation of the RNA to the situs for protein translation, actual translation of protein from the RNA, and possibly even independent catalytic activity which may be engaged in by the RNA. The overall effect of such interference with the RNA function is to cause the papillomavirus to lose the benefit of the RNA and, overall, to experience interference with expression of the viral genome. Such interference is generally fatal.

In accordance with the present invention, it is preferred to provide oligonucleotides and oligonucleotide analogs designed to interfere with messenger RNAs determined to be of enhanced metabolic significance to the virus. As explained above,the E1, E2, E7, or E6-7 papillomavirus mRNAs are preferred targets.

It is also preferred to interfere with RNA coded by nucleotides substantially equivalent to nucleotides 2443 through 3080 or 89 through 304 of bovine papillomavirus-1 genome since these are believed to represent a particularly vulnerable situs for attack as they are believed to code for a plurality of RNAs leading to essential proteins. It will be appreciated that differing papillomaviruses will have somewhat different structures from bovine papillomavirus-1, but that essentially similar areas may be routinely determined.

Figures 3, 4, and 5 represent these areas on the bovine papillomavirus-1 genome and any oligonucleotide or oligonucleotide analog designed to interfere with RNA coded by their counterparts in particular papillomaviruses is likely to have especial utility in interfering with operation of those papillomaviruses. Exemplary oligonucleotides targeted at the E2 mRNA of bovine papillomavirus-1 are set forth in Table 2.

TABLE 2

BPV-1 E2 antisense oligonucleotides

Oligo-nucleotide	5'----------3'	Comments
001(LC001.AB1)	AGGTTTGCACCCGACTATGCAAGTACAAAT	mRNA cap region
002(LC002.AB1)	TATGCAAGTACAAAT	mRNA cap region
003(LC003.AB1)	CGTTCGCATGCTGTCTCCATCCTCTTCACT	initiation of translation
004(LC004.AB1)	GCATGCTGTCTCCAT	initiation of translation
005(LC005.AB1)	AAATGCGTCCAGCACCGGCCATGGTGCAGT	transrepressor start
006(LC006.AB1)	AGCACCGGCCATGGT	transrepressor start
007(LC007.AB1)	CAATGGCAGTGATCAGAAGTCCAAGCTGGC	translational termination
008(LC008.AB1)	GCAGTGATCAGAAGT	translational termination
009(LC009.AB1)	ATTGCTGCAGCTTAAACCATATAAAATCTG	3' untranslated region
010(LC010.AB1)	CTTAAACCATATAAA	3' untranslated region
011(LC011.AB1)	AAAAAAAGATTTCCAATCTGCATCAGTAAT	5' untranslated region
012(LC012.AB1)	AAGATTTCCAATCTG	5' untranslated region
013(LC013.AB1)	CAGTGTCCTAGGACAGTCACCCCTTTTTTC	5' coding region
014(LC014.AB1)	GGACAGTCACCCCTT	5' coding region
015(LC015.AB1)	TGTACAAATTGCTGTAGACAGTGTACCAGT	mid coding region
016(LC016.AB1)	GCTGTAGACAGTGTA	mid coding region
017(LC017.AB1)	GTGCGAGCGAGGACCGTCCCGTACCCAACC	3' coding region
018(LC018.AB1)	GGACCGTCCCGTACC	3' coding region
019(LC019.AB1)	TTTAACAGGTGGAATCCATCATTGGTGGTG	5' coding region
020(LC020.AB1)	GGAATCCATCATTGG	5' coding region

Examplary oligonucleotides targeted to the translation initiation codon of HPV-11 are set forth in Table 3.

TABLE 3

Antisense Oligonucleotides Targeted to the Translation Initiation Codon of HPV-11

Compound Number	5'----------3'	Sequence ID
I2100	GCTTCCATCTTCCTC	1
I2101	GCTTCCATCTTCCTCG	2
I2102	TGCTTCCATCTTCCTCG	3
I2103	TGCTTCCATCTTCCTCGT	4
I2104	TTGCTTCCATCTTCCTCGT	5
I2105	TTGCTTCCATCTTCCTCGTC	6

Thus, it is preferred to employ any of the twenty oligonucleotides (or their analogs) set forth above or any of the similar oligonucleotides (or analogs) which persons of ordinary skill in the art can prepare from knowledge of

the respective, preferred regions of the E2 ORF of a papillomavirus genome as discussed above. Similar tables may be generated for the other preferred ORF targets of papillomaviruses, E1, E7, and E6-7 from knowledge of the sequences of those respective regions.

It is not necessary that the oligonucleotides or analogs be precisely as described in the foregoing table or precisely as required by a slavish interpretation of the mapping of the papillomavirus genome. Rather, the spirit of this invention permits some digression from strict adherence to the genome structure and it literal "translation" into oligonucleotide. Modifications of such structures may be made so long as the essential hybridizing function of the oligonucleotides and their analogs results.

Similarly, it will be appreciated that species variation among the various papillomaviruses occur. While the various regions, e.g. E2, E1, etc., are very similar from species to species, some differentiation occurs. Alteration in the oligonucleotides and analogs to account for these variations is specifically contemplated by this invention.

The oligonucleotides and analogs used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed, however. Useful oligonucleotides may also be conveniently acquired through fermentation techniques, which may be preferred when large amounts of material are desired. The actual synthesis of the oligonucleotides are well within the talents of the routineer.

It is also known to use similar techniques to prepare other oligonucleotide analogs such as the phosphothioates and alkylated derivatives.

A preferred assay to test the ability of E2 specific

antisense oligonucleotides to inhibit E2 expression was based on the well documented transactivation properties of E2. Spalholtz et al., J. Virol. 61, 2128-2137 (1987). A reporter plasmid (E2RECAT) was constructed to contain the E2 responsive element, which functions as an E2 dependent enhancer. E2RECAT also contains the SV40 early promoter, an early polyadenylation signal, and the chloramphenicol acetyl transferase gene (CAT). Within the context of this plasmid, CAT expression is dependent upon expression of E2. The dependence of CAT expression on the presence of E2 has been tested by transfection of this plasmid into C127 cells transformed by BPV-1, uninfected C127 cells and C127 cells cotransfected with E2RECAT and an E2 expression vector.

Antisense oligonucleotides were designed to target the major E2 transactivator mRNA (Figure 6). Targets included, but were not limited to, the mRNA CAP region, the translation initiation codon, translation termination codon, and polyadenylation signal. Fifteen or 30 residue oligonucleotides complementary to the various targets were synthesized with a wild type phophosphodiester internucleosidic linkage or a modified phosphorothioate internucleosidic linkage. Oligonucleotides targeted to the mRNA CAP region (I1751) and the translation codon for the E2 transactivator (I1753) were shown to reduce E2 transactivation at 1 micromolar concentrations in preliminary screens (Figure 7). Oligonucleotide I1756 targeted to the translation initiation codon of the E2 transrepressor (Figure 6) was able to give partial relief of transrepression as demonstrated by and increase in CAT activity (Figure 7). Other oligonucleotides of similar length and base composition, but targeted to other areas of the E2 mRNA, as well as other nonsense control, failed to give an antisense effect. In general, oligonucleotides with the phosphorothioate internucleocidic linkage modification were more effective than oligonucleotides of the same sequence containing the natural phosphodiester internucleosidic linkage. This is presumably due to the

increased resistance of phosphorothioates to nucleases contained in the serum and within the cell. Dose response curves show that I1753 has an 50 % inhibitory concentration (IC_{50}) in the range of 50 to 100 nM while I1751 has an IC_{50} ten fold higher in the range of 500 nM (Figure 8). After identification of the translation initiation codon of the E2 transactivator and transrepressor as successful antisense targets an additional set of phosphorothioates were designed to more carefully probe the regions (Figure 9). These data showed that 15 to 20 mer oligonucleotides that covered the appropriate AUG could inhibit either E2 transactivation or transrepression (Figure 10 and 11).

In order to determine the consequences of reduction of E2 transactivator *in situ* on the biology of the BPV-1, antisense oligonucleotides were tested for the ability to inhibit or attenuate BPV-1 transformation of C127 cells (Figure 12). Dose response curves for I1751 and I1753 showed that I1753 had an IC_{50} in the range of 10 nM while I1751 had an IC_{50} in the range of 100 nM (Figure 13) this 10 fold difference in the IC_{50} of these two compounds in this assay is similar to that observed in the inhibition of transactivation assay suggesting that the translation initiation codon is a better target.

To test the effect of E2 targeted antisense oligonucleotides on the ability of BPV-1 to replicate it genome, I-38 cells stably transformed by BPV-1 were treated with I1753 and I1751 and the viral DNA quantitated (Figure 14). After 48 hours of treatment at 1 micromolar concentration the viral DNA copy number on a per cell basis was reduced by factor of approximately 3. During the course of this assay the cells divided between 2 and 3 times. This data suggests that the viral DNA failed to replicate synchronously with the cellular DNA.

In order to test the effect of I1753 on E2 protein synthesis, I-38 cells were metabolically labelled and immunoprecipitated with an E2 specific monoclonal antibody. In cells not exposed to oligonucleotide or cells treated

with sense or irrelevant oligonucleotides the 46 kd E2 protein is present (Figure 15). In cells treated with oligonucleotides targeted to the E2, the 46 kd band is lost suggesting that the oligonucleotide is operating by hybridization arrest of translation.

The oligonucleotides and oligonucleotide analogs of this invention can be used in diagnostics, therapeutics and as research reagents and kits. For therapeutic use, the oligonucleotide or oligonucleotide analog is administered to an animal suffering from a papillomavirus infection such as warts of the hands, warts of the feet, warts of the larynx, condylomata acuminata, epidermodysplasia verruciformis, flat cervical warts, cervical intraepithelial neoplasia, or any other infection involving a papillomavirus. It is generally preferred to apply the therapeutic agent in accordance with this invention topically or interlesionally. Other forms of administration, such as transdermally, or intramuscularly may also be useful. Inclusion in suppositories is presently believed to be likely to be highly useful. Use of the oligonucleotides and oligonucleotide analogs of this invention in prophylaxis is also likely to be useful. Such may be accomplished, for example, by providing the medicament as a coating in condoms and the like. Use of pharmacologically acceptable carriers is also preferred for some embodiments.

The present invention is also useful in diagnostics and in research. Since the oligonucleotides and oligonucleotide analogs of this invention hybridize to papillomavirus, sandwich and other assays can easily be constructed to exploit this fact. Provision of means for detecting hybridization of oligonucleotide or analog with papillomavirus present in a sample suspected of containing it can routinely be accomplished. Such provision may include enzyme conjugation, radiolabelling or any other suitable detection systems. Kits for detecting the presence or absence of papillomavirus may also be prepared.

EXAMPLE 1 Inhibition of Expression of BPV-1 E2 by Antisense Oligonucleotides.

BPV-1 transformed C127 cells are plated in 12 well plates. Twenty four hours prior to transfection with E2RE1 cells are pretreated by addition of antisense oligonucleotides to the growth medium at final concentrations of 5, 15 and 30 mM. The next day cells are transfected with 10 μg of E2RE1CAT by calcium phosphate precipitation. Ten micrograms of E2RE1CAT and 10 μg of carrier DNA (PUC 19) are mixed with 62 μl of 2 M $CaCl_2$ in a final volume of 250 μl of H_20, followed by addition of 250 μl of 2X HBSP (1.5 mM Na_2PO_2. 10 mM KCl, 280 mM NaCl, 12 mM glucose and 50 mM HEPES, pH 7.0) and incubated at room temperature for 30 minutes. One hundred microliters of this solution is added to each test well and allowed to incubate for 4 hours at 37°C. After incubation cells are glycerol shocked for 1 minute at room temperature with 15% glycerol in 0.75 mM Na_2PO_2, 5 mM KCl, 140 mM NaCl, 6 mM glucose and 25 mM HEPES, pH 7.0. After shocking, cells are washed 2 times with serum free DMEM and refed with DMEM containing 10% fetal bovine serum and antisense oligonucleotide at the original concentration. Forty eight hours after transfection cells are harvested and assayed for CAT activity.

For determination of CAT activity, cells are washed 2 times with phosphate buffered saline and collected by scraping. Cells are resuspended in 100 ul of 250 mM Tris-HCl, pH 8.0 and disrupted by freeze-thawing 3 times. Twenty four microliters of cell extract is used for each assay. For each assay the following are mixed together in an 1.5 ml Eppendorff tube: 25 μl of cell extract, 5 μl of 4 mM acetyl coenzyme A, 18 μl H_2O and 1 ul ^{14}C-chloramphenicol, 40-60 mCi/mM and incubated at 37°C for 1 hour. After incubation chloramphenicol (acetylated and nonacetylated forms) are extracted with ethyl acetate and evaporated to dryness. Samples are resuspended in 25 μl of

ethyl acetate and spotted onto a TLC plate and chromatograph in chloroform:methanol (19:1). TLC are analyzed by autoradiography. Spots corresponding to acetylated and nonacetylated ^{14}C-chloramphenicol are excised from the TLC plate and counted by liquid scintillation for quantitation of CAT activity. Antisense oligonucleotides that depress CAT activity in a dose dependent fashion are considered positives.

EXAMPLE 2 Inhibition of HPV E2 Expression by Antisense Oligonucleotides.

The assay for inhibition of HPV E2 by antisense oligonucleotides is essentially the same as that for BPV-1 E2. For HPV assays appropriate HPVs are co-transfected into either CV-1 or A431 cells with PSV2NEO cells using the calcium phosphate method described above. Cells which take up DNA are selected for by culturing in media containing the antibiotic G418. G418 resistant cells are then analyzed for HPV DNA and RNA. Cells expressing E2 are used as target cells for antisense studies. For each antisense oligonucleotide cells are pretreated as above followed by transfection with E2RE1CAT and analysis of CAT activity as above. Antisense oligonucleotides are considered to have a positive effect if they can depress CAT activity in a dose dependent fashion.

EXAMPLE 3 Inhibition of HPV E7 Expression by Antisense Oligonucleotides.

The E7 of HPV-16 has been shown to be capable of transactivating the Ad E2 promoter (Phelps, W. C. Yee, C. L., Munger, K., and Howley, P. M. 1988. The Human Papillomavirus Type 16 E7 Gene Encodes Transactivation and Transformation Functions Similar to Those of Adenovirus E1A. Cell 53:539-547. To monitor this activity a plasmid is constructed which contained the chloramphenicol transferase gene under the control of the Ad E2 promoter (AdE2CAT). Under the conditions of this assay CAT

expression is dependent on expression of HPV E7. For this assay cell lines are developed that contain the HPV E7 under the control of the SV40 early promoter. For each antisense oligonucleotide cells are pretreated as above followed by transfection with AdE2CAT and analysis of CAT activity as above.

EXAMPLE 4 Inhibition of Expression of BPV-1 E1 by Antisense Oligonucleotides.

The E1 of BPV-1 has been shown to be a regulator of viral genome replication. To test the effects of antisense oligonucleotides on viral replication C127 cells infected with BPV-1 are treated with E1 specific antisense oligonucleotides by addition of oligonucleotides to the growth medium at final concentrations of 5, 15 and 30 μM. The effects of the oligonucleotides are evaluated by a routine Northern blot analysis for quantitation of both E1 specific RNA as well as total viral RNA. In addition, the effects of antisense oligonucleotides on viral genome copy number are determined by Southern blot on total genomic DNA.

EXAMPLE 5 Determination of Efficacy of BPV-1 Antisense Oligonucleotides on Experimentally Induced Bovine Fibropapillomas.

Multiple bovine fibropapillomas are induce on calves by direct infection of the epidermis with purified BPV-1. Upon development, fibropapillomas are treated with oligonucleotides that had positive results in vitro as well as controls. Antisense oligonucleotides that induce regression of the fibropapilloma are considered as positives.

EXAMPLE 6 Design and Synthesis of Oligonucleotides Complementary to E2 mRNA

Antisense oligonucleotides were designed to be complementary to various regions of the E2 mRNA as defined

by the published nucleotide sequence of BPV-1 (Chen, E. Y., Howley, P. M., Levinson, A. D., and Seeburg, P. H. 1982. The primary structure and genetic organization of the bovine papillomavirus type 1 genome. Nature 299:529-534) and cDNA structure of the major E2 transactivator mRNA (Yang, Y. C., Okayama, H., and Howley, P. M. 1985. Bovine papillomavirus contains multiple transforming genes. Proc. Natl. Acad. Sci. USA 82:1030-1034). Antisense oligonucleotides targeted to the translation initiation codon of HPV-11 E2 were based on the published sequence of HPV-11 (Dartmann, K., Schwarz, E., Gissamnn, L., and zur Hausen. 1986. Virology 151:124-130). Solid-phase oligodeoxyribonucleotide syntheses were performed using an Applied Biosystems 380B automated DNA synthesizer. For the phosphorothioate oligonucleotides, sulfurization was performed after each coupling using 0.2 M 3H-1,2-Benzodithiol-3-one-1,1-dioxide dissolved in acetonitrile as described by Iyer et al. (Iyer, R. P., Phillips, L. R., Egan, W., Regan, J. and Beaucage, S. L. 1990. The Automated Synthesis of Sulfur-Containing Oligodeoxyribonucleotides Using ^{3}H-1,2-Bensodithiol-3-one 1,1-Dioxide as a Sulfur-Transfer Reagent. J. Org. Chem. 55:4693-4699). To insure complete thioation, the growing oligonucleotide was capped after each sulfurization step. After cleavage from the synthesis matrix, deprotection and detriylation oligonucleotides were ethanol precipitated twice out NaCl and suspended in water. The concentration of oligonucleotide was determined by optical density at 260 nm. For use in cell culture assays oligonucleotides were routinely diluted to 100 micromolar stocks and stored at -80°C until use. The purity, integrity, and quantity of the oligonucleotide preparations were determined by electrophoresis on 20% acrylamide 7 M urea gels (40 cm x 20 cm x 0.75 mm) prepared as described by Maniatis et al. (Maniatis, T., Fritsch, E. F. and Sambrook, J. *Molecular Cloning: A Laboratory Manual*: Cold Spring Harbor Laboratory: New York, 1982). Electrophoresed

oligonucleotides were visualized within the gel by staining with "Stains-all" , 1-ethyl-2[3-(1-ethylnapthol[1,2-d]-thiazolin-2-ylidene)-2-Methyl-Propenyl[napthol[1,2d]-thiazolium bromide purchased from Sigma, E-9379, (Dahlberg, A. E., Digman, C. W. and Peacock, A. C. 1969. J. Mol. Biol. 41:39).

EXAMPLE 7 Molecular Constructs

The E2 chloramphenicol acetyl transferase (CAT) reporter plasmid used in this study has been previously described (Spalholz, B. A., Byrne, J. C. and Howley, P. M. 1988. Evidence for Cooperativity between E2 Binding Sites in E2 trans-regulation of Bovine Papillomavirus Type 1. J. Virol. 62:3143-3150). Briefly, the E2 responsive element, E2RE1, (nt 7611-7806) of BPV-1 was reconstructed using oligonucleotides and cloned into pSV2CAT that had been deleted of the SV40 enhancer, Sph1 fragment. Expression of CAT from this plasmid has been shown to be dependent upon full length E2. Plasmid C59 contain an E2 cDNA expressed from the simian virus 40 promoter and enhancer and has been described in detail elsewhere (Yang, Y.-C., Okayama, H. and Howley, P. M. 1985. Bovine papillomavirus contains multiple transforming genes. Proc. Natl. Acad. Sci. USA 82:1030-1034). Two HPV-11 full length E2 expression constructs were made. IPV115 contains the XmnI fragment of HPV-11 (nt 2665-4988) cloned into the SmaI site of pMSG purchased from Pharmacia (catalog number 27-4506), IPV118 contains the same HPV-11 XmnI fragment cloned into the SmaI site of pSVL (Pharmacia, catalog number 27-4509).

EXAMPLE 8 Cell Lines

Mouse C127 cells (Dvoretzky, I. Schober, R., and Lowy, D. 1980. Focus Assay in Mouse Cells for Bovine Papillomavirus typ 1. Virology 103:369-375) were grown in Dulbecco's Modified Eagle's medium supplemented with 10% fetal bovine serum, penicillin (100U/ml), streptomycin (100ug/ml), and L-glutamine (4 mM). I-38 cell line was derived from a

single focus of C127 cells transformed by purified BPV-1 (Cowsert, L. M., Lake, P., and Jenson, A. B. 1987. Topographical and conformational Epitopes of Bovine Papillomavirus type 1 Defined by Monoclonal Antibodies. JNCI 79:1053-1057).

EXAMPLE 9 Oligonucleotide Inhibition of E2 Dependent Transactivation Assays

To test an oligonucleotide's ability to inhibit E2 transactivation or transrepression, I-38 cells were plated at 1 x 10^4 cells per cm^2 in 60 mm petri dishes 24 hours before transfection. Sixteen hours prior to transfection media was aspirated and replaced with media containing oligonucleotide at the appropriate concentration. One hour prior to transfection media was aspirated and replaced with fresh media without oligonucleotide. Cells were transfected by the calcium phosphate precipitation method as described by Graham et al. 1973 (Graham, F. L. and van der Eb, A. J. 1973. A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA. Virology 52:456-461) with a total of 20 micrograms of DNA in one milliliter of precipitate. Each 60 mm dish received 200 microliters of precipitate containing 4 mictograms of DNA. Four hours after the addition of precipitated DNA the supernatant was aspirated and the cells treated with 15% glycerol (Frost, E. and Williams, J. 1978. Mapping Temperature-Sensitive and host-range mutation of Adenovirus type 5 by Marker Rescue. virology 91:39-50). After washing cells were refed with media containing oligonucleotide at the original concentration and incubated for 48 hours.

While a number of specitic embodiments have been set forth, the present invention is to be limited only in accordance with the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Crooke, Stanley T., Mirabelli, Christopher K., Ecker, David J., Coswert, Lex M.

(ii) TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE INHIBITORS OF PAPILLIMAVIRUS

(iii) NUMBER OF SEQUENCES: 6

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & Norris

(B) STREET: One Liberty Place - 46th Floor

(C) CITY: Philadelphia

(D) STATE: PA

(E) COUNTRY: USA

(F) ZIP: 19103

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE

(B) COMPUTER: IBM PS/2

(C) OPERATING SYSTEM: PC-DOS

(D) SOFTWARE: WORDPERFECT 5.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: PCT/US90/07067

(B) FILING DATE: December 3, 1990

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Jane Massey Licata

(B) REGISTRATION NUMBER: 32,257

(C) REFERENCE/DOCKET NUMBER: ISIS-0033

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (215) 568-3100

(B) TELEFAX: (215) 568-3439

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 15

(B) TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GCTTCCATCT TCCTC 15

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 16

(B) TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GCTTCCATCT TCCTCG 16

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17

(B) TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

TGCTTCCATC TTCCTCG 17

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18

(B) TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TGCTTCCATC TTCCTCGT 18

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19

(B) TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TTGCTTCCAT CTTCCTCGT 19

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20

(B) TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

TTGCTTCCAT CTTCCTCGTC 20

WHAT IS CLAIMED IS:

1. An oligonucleotide or oligonucleotide analog, hybridizable with a messenger RNA from a papillomavirus, that inhibits the function of said messenger RNA when hybridized therewith.

2. The oligonucleotide or oligonucleotide analog of claim 1 wherein said messenger RNA comprises at least a portion of the sequence of papillomavirus E2 RNA.

3. The oligonucleotide or oligonucleotide analog of claim 1 wherein said messenger RNA comprises at least a portion of the sequence of papillomavirus E1 RNA.

4. The oligonucleotide or oligonucleotide analog of claim 1 wherein said messenger RNA comprises at least a portion of the sequence of papillomavirus E7 RNA.

5. The oligonucleotide or oligonucleotide analog of claim 1 wherein said messenger RNA comprises at least a portion of the sequence of papillomavirus E6-7 RNA.

6. The oligonucleotide or oligonucleotide analog of claim 1 complementary with at least a portion of the E2 transactivator portion of papillomavirus RNA.

7. The oligonucleotide or oligonucleotide analog of claim 6 wherein said transactivator portion corresponds to nucleotides 2443 through 3080 in bovine papillomavirus-1.

8. The oligonucleotide or oligonucleotide analog of claim 1 complementary with at least a portion of the 5' untranslated region of papillomavirus RNA.

9. The oligonucleotide or oligonucleotide analog of claim 8 wherein said 5' untranslated portion corresponds to nucleotides 89 through 304 in bovine papillomavirus-1.

10. The oligonucleotide or oligonucleotide analog of claim 1 comprising from about 3 to about 50 base units.

11. The oligonucleotide or oligonucleotide analog of claim 1 comprising from about 8 to about 25 base units.

12. The oligonucleotide or oligonucleotide analog of claim 1 comprising from about 12 to about 20 base units.

13. The oligonucleotide or oligonucleotide analog of claim 1 which inhibits the translation of said messenger RNA into protein when hybridized therewith.

14. An oligonucleotide or oligonucleotide analog comprising a base sequence in accordance with at least one of the sequences of Table 2.

15. A method of modulating the expression of a papillomavirus comprising contacting messenger RNA from said papillomavirus with an oligonucleotide or oligonucleotide analog hybridizable with a messenger RNA from the papillomavirus, that inhibits the function of said messenger RNA when hybridized therewith.

16. The method of claim 15 wherein said messenger RNA comprises at least a portion of the sequence of papillomavirus E2 RNA.

17. The method of claim 15 wherein said messenger RNA comprises at least a portion of the sequence of papillomavirus E1 RNA.

18. The method of claim 15 wherein said messenger RNA comprises at least a portion of the sequence of papillomavirus E7 RNA.

19. The method of claim 15 wherein said messenger RNA comprises at least a portion of the sequence of papillomavirus E6-7 RNA.

20. The method of claim 15 wherein said oligonucleotide or oligonucleotide analog is complementary with at least a portion of the E2 transactivator portion of papillomavirus RNA.

21. The method of claim 20 wherein said transactivator portion corresponds to nucleotides 2443 through 3080 in bovine papillomavirus-1.

22. The method of claim 15 wherein said oligonucleotide or oligonucleotide analog is complementary with at least a portion of the 5' untranslated region of papillomavirus RNA.

23. The method of claim 22 wherein said 5' untranslated portion corresponds to nucleotides 89 through 304 in bovine papillomavirus-1.

24. The method of claim 15 wherein said oligonucleotide or oligonucleotide analog comprises from about 3 to about 50 base units.

25. The method of claim 15 wherein said oligonucleotide or oligonucleotide analog comprises from about 8 to about 25 base units.

26. The method of claim 15 wherein said oligonucleotide or oligonucleotide analog comprises from about 12 to about 20 base units.

27. The method of claim 15 wherein the translation of said messenger RNA into protein is inhibited.

28. The method of claim 15 wherein the translocation of said messenger RNA into the cytoplasm is inhibited.

29. A method of modulating the effects of a papillomavirus infection in an animal comprising contacting the animal with an oligonucleotide or oligonucleotide analog hybridizable with a messenger RNA from the papillomavirus, that inhibits the function of said messenger RNA when hybridized therewith.

30. The method of claim 29 wherein said messenger RNA comprises at least a portion of the sequence of papillomavirus E2 RNA.

31. The method of claim 29 wherein said messenger RNA comprises at least a portion of the sequence of papillomavirus E1 RNA.

32. The method of claim 29 wherein said messenger RNA comprises at least a portion of the sequence of papillomavirus E7 RNA.

33. The method of claim 29 wherein said messenger RNA comprises at least a portion of the sequence of papillomavirus E6-7 RNA.

34. The method of claim 29 wherein said oligonucleotide or oligonucleotide analog is complementary with at least a portion of the E2 transactivator portion of papillomavirus RNA.

35. The method of claim 34 wherein said transactivator portion corresponds to nucleotides 2443 through 3080 in bovine papillomavirus-1.

36. The method of claim 29 wherein said oligonucleotide or oligonucleotide analog is complementary with at least a portion of the 5' untranslated region of papillomavirus RNA.

37. The method of claim 36 wherein said 5' untranslated portion corresponds to nucleotides 89 through 304 in bovine papillomavirus-1.

38. The method of claim 29 wherein said oligonucleotide or oligonucleotide analog comprises from about 3 to about 50 base units.

39. The method of claim 29 wherein said oligonucleotide or oligonucleotide analog comprises from about 8 to about 25 base units.

40. The method of claim 29 wherein said oligonucleotide or oligonucleotide analog comprises from about 12 to about 20 base units.

41. The method of claim 29 wherein the translation of said messenger RNA into protein is inhibited.

42. The method of claim 42 wherein the infection is warts of the hands, warts of the feet, warts of the larynx, condylomata acuminata, epidermodysplasia verruciformis, flat cervical warts, or cervical intraepithelial neoplasia.

43. A method for detecting the presence or absence of papillomavirus in a sample suspected of containing it comprising

contacting the sample with an oligonucleotide or oligonucleotide analog hybridizable with a messenger RNA from a papillomavirus,and

detecting the hybridization.

44. The method of claim 43 wherein said messenger RNA comprises at least a portion of the sequence of at least one of papillomavirus E2, E1, E7, and E6-7 RNAs.

45. The method of claim 43 wherein said oligonucleotide or oligonucleotide analog is complementary with at least a portion of the E2 transactivator portion of papillomavirus RNA.

46. The method of claim 45 wherein said transactivator portion corresponds to nucleotides 2443 through 3080 in bovine papillomavirus-1.

47. The method of claim 43 wherein said oligonucleotide or oligonucleotide analog is complementary with at least a portion of the 5' untranslated region of papillomavirus RNA.

48. The method of claim 47 wherein said 5' untranslated portion corresponds to nucleotides 89 through 304 in bovine papillomavirus-1.

49. The method of claim 43 wherein said detecting step comprises detecting the formation of labelled protein coded for by the messenger RNA.

50. The method of claim 43 wherein said detecting step comprises detecting operation of a protein coded for by the messenger RNA.

51. A kit for the detection of the presence or absence of papillomavirus in a sample suspected of containing it comprising

oligonucleotide or oligonucleotide analog hybridizable with a messenger RNA from a papillomavirus, and

means for detecting the hybridization.


BPV-1
1
2
3
E6
E8
E7
E1
E2
E4
E3
E5
L2
L1
49
501
1099
1479
449
859
813
2581
3837
3173
3526
2663
3267
3551
3714
4010
4172
5593/5597
7093
0
1000
2000
3000
4000
5000
6000
7000
7946

Fig. 1A


HPV-1a
1
2
3
E7
E6
E8
E1
E4
E5
E2
L2
L1
502 807
86 523
45 353
773 2647
3157 3558 3877 4152
2568 3794 3894 5412
5347 6936
0
1000
2000
3000
4000
5000
6000
7000
7815

Fig. 1B


HPV-11
1
2
3
E6
E7
E1
E2
E4
E5a
E5b
L2
L1
18
494
715
823
551
2696
2778
3231
3578
3823
3662
4143
3987
4367
4408
5660
5781
7273
0
1000
2000
3000
4000
5000
6000
7000
7931

Fig. 1C


HPV-16
1
2
3
E6
E7
E1
E2
E4
E5
L2
L1
65
544
855/859
2811
2726
3850
3333
3617
3864
4097
4134
5654
5527
7152
0
1000
2000
3000
4000
5000
6000
7000
7905

Fig. 1D

Fig. 2


TRANSLATION FRAME
1
2
3
E6
E8
E2
E7
E4
L2
L1
E1
E3
E5
LCR
P7185
P7940
P890
P2443
P3080
AE
AL
PL
P89
7200
7946/1
1000
2000
3000
4000
5000
6000
7000


SPECIES
FIRST POTENTIAL CODING ORF
A 7185 4203 ?
B 7879 864 3225 4203 E6
C 89 304 3225 4203 E6/E4
D 89 (304) 4203 ?
E 89 304 528 864 3225 4203 E6/E7
F 89 (864) (3225) 4203 E6
G 89 (304)(528) 4203 (E6/E7)
H 89 4203 E6
I 138 304 528 1235 3225 4203 E6/E7
J 890 1235 3225 4203 E8/E2
K (1235) (3225) 4203 ?
L (2505) (3225) 4203 ?
M 2443 2505 3225 4203 E5
N 2443 4203 E2
O 3080 4203 E2
P 7255 4203 E6
Q 7232 864 3225 4203 E6
R 7246 7385 3225 4197 E4
S 7217 7385 3605 4203 E2
T 7269 7385 3605 3764 5609 L1 7175
U 4096 L2 7175

```
   1 ATTTGTACTT GCATAGTCGG GTGCAAACCT TTCGCTTTGA GCAGCCATGC ACAGATGAAT
  61 CGGGTGAGCA ACCTTTTAAT ATTACTGATG CAGATTGGAA ATCTTTTTTT GTAAGGTTAT
 121 GGGGGCGTTT AGACCTGATT GACGAGGAGG AGGATAGTGA AGAGGATGGA GACAGCATGC
 181 GAACGTTTAC ATGTAGCGCA AGAAACACAA ATGCAGTTGA TTGAGAAAAG TAGTGATAAG
 241 TTGCAAGATC ATATACTGTA CTGGACTGCT GTTAGAACTG AGAACACACT GCTTTATGCT
 301 GCAAGGAAAA AAGGGGTGAC TGTCCTAGGA CACTGCAGAG TACCACACTC TGTAGTTTGT
 361 CAAGAGAGAG CCAAGCAGGC CATTGAAATG CAGTTGTCTT TGCAGGAGTT AAGCAAAACT
 421 GAGTTTGGGG ATGAACCATG GTCTTTGCTT GACACAAGCT GGGACCGATA TATGTCAGAA
 481 CCTAAACGGT GCTTTAAGAA AGGCGCCAGG GTGGTAGAGG TGGAGTTTGA TGGAAATGCA
 541 AGCAATACAA ACTGGTACAC TGTCTACAGC AATTTGTACA TGCGCACAGA GGACGGCTGG
 601 CAGCTTGCGA AGGCTGGGGC TGACGGAACT GGGCTCTACT ACTGCACCAT GGCCGGTGCT
 661 GGACGCATTT ACTATTCTCG CTTTGGTGAC GAGGCAGCCA GATTTAGTAC AACAGGGCAT
 721 TACTCTGTAA GAGATCAGGA CAGAGTGTAT GCTGGTGTCT CATCCACCTC TTCTGATTTT
 781 AGAGATCGCC CAGACGGAGT CTGGGTCGCA TCCGAAGGAC CTGAAGGAGA CCCTGCAGGA
 841 AAAGAAGCCG AGCCAGCCCA GCCTGTCTCT TCTTTGCTCG GCTCCCCCGC CTGCGGTCCC
 901 ATCAGAGCAG GCCTCGGTTG GGTACGGGAC GGTCCTCGCT CGCACCCCTA CAATTTTCCT
 961 GCAGGCTCGG GGGGCTCTAT TCTCCGCTCT TCCTCCACCC CGGTGCAGGG CACGGTACCG
1021 GTGGACTTGG CATCAAGGCA GGAAGAAGAG GAGCAGTCGC CCGACTCCAC AGAGGAAGAA
1081 CCAGTGACTC TCCCAAGGCG CACCACCAAT GATGGATTCC ACCTGTTAAA GGCAGGAGGG
1141 TCATGCTTTG CTCTAATTTC AGGAACTGCT AACCAGGTAA AGTGCTATCG CTTTCGGGTG
1201 AAAAAGAACC ATAGACATCG CTACGAGAAC TGCACCACCA CCTGGTTCAC AGTTGCTGAC
1261 AACGGTGCTG AAAGACAAGG ACAAGCACAA ATACTGATCA CCTTTGGATC GCCAAGTCAA
```

Fig. 3A

```
1321 AGGCAAGACT TTCTGAAACA TGTACCACTA CCTCCTGGAA TGAACATTTC CGGCTTTACA
1381 GCCAGCTTGG ACTTCTGATC ACTGCCATTG CCTTTTCTTC ATCTGACTGG TGTACTATGC
1441 CAAATCTATG GTTTCTATTG TTCTTGGGAC TAGTTGCTGC AATGCAACTG CTGCTATTAC
1501 TGTTCTTACT CTTGTTTTTT CTTGTATACT GGGATCATTT TGAGTGCTCC TGTACAGGTC
1561 TGCCCTTTTA ATGCCTTTAC ATCACTGGCT ATTGGCTGTG TTTTTACTGT TGTGTGGATT
1621 TGATTTGTTT TATATACTGT ATGAAGTTTT TTCATTTGTG CTTGTATTGC TGTTTGTAAG
1681 TTTTTTACTA GAGTTTGTAT TCCCCCTGCT CAGATTTTAT ATGGTTTAAG CTGCAGCAAT
1741 AAAAATGAGT GCACGAAAAA G
```

Fig. 3B

```
  1 ATTTGTACTT GCATAGTCGG GTGCAAACCT TTCGCTTTGA GCAGCCATGC ACAGATGAAT
 61 CGGGTGAGCA ACCTTTTAAT ATTACTGATG CAGATTGGAA ATCTTTTTTT GTAAGGTTAT
121 GGGGGCGTTT AGACCTGATT GACGAGGAGG AGGATAGTGA ACAGGATGGA GACAGCATGC
181 GAACGTTTAC ATGTAGCGCA AGAAACACAA ATGCAGTTGA TTGAGAAAAG TAGTGATAAG
241 TTGCAAGATC ATATACTGTA CTGGACTGCT GTTAGAACTG AGAACACACT GCTTTATGCT
301 GCAAGGAAAA AAGGGGTGAC TGTCCTAGGA CACTGCAGAG TACCACACTC TGTAGTTTGT
361 CAAGAGAGAG CCAAGCAGGC CATTGAAATG CAGTTGTCTT TGCAGGAGTT AAGCAAAACT
421 GAGTTTGGGG ATGAACCATG GTCTTTGCTT GACACAAGCT GGGACCGATA TATGTCAGAA
481 CCTAAACGGT GCTTTAAGAA AGGCGCCAGG GTGGTAGAGG TGGAGTTTGA TGGAAATGCA
541 AGCAATACAA ACTGGTACAC TGTCTACAGC AATTTGTACA TGCGCACAGA GGACGGCTGG
601 CAGCTTGCGA AGGCTGGGGC TGACGGAACT GGGCTCTA
```

Fig. 4


```
  1 ACATGGACCT GAAACCTTTT GCAAGAACCA ATCCATTCTC AGGGTTGGAT TGTCTGTGGT
 61 GCAGAGAGCC TCTTACAGAA GTTGATGCTT TTAGGTGCAT GGTCAAAGAC TTTCATGTTG
121 TAATTCGGGA AGGCTGTAGA TATGGTGCAT GTACCATTTG TCTTCAAAAC TGTTTAGCTA
181 CTGAAAGAAG ACTTTGGCAA GGTGTTCCAG TAACAG
```

Fig. 5



Oligo	5'----------3'	Comments
LC001.ABI	AGGTTTGCACCCGACTATGCAAGTACAAAT	mRNA cap region
LC002.ABI	TATGCAAGTACAAAT	mRNA cap region
LC003.ABI	CGTTCGCATGCTGTCTCCATCCTCTTCACT	initiation of translation
LC004.ABI	GCATGCTGTCTCCAT	initiation of translation
LC005.ABI	AAATGCGTCCAGCACCGGCCATGGTGCAGT	transrepressor start
LC006.ABI	AGCACCGGCCATGGT	transrepressor start
LC007.ABI	CAATGGCAGTGATCAGAAGTCCAAGCTGGC	translational termination
LC008.ABI	GCAGTGATCAGAAGT	translational termination
LC009.ABI	ATTGCTGCAGCTTAAACCATATAAAATCTG	3' untranslated region
LC010.ABI	CTTAAACCATATAAA	3' untranslated region
LC011.ABI	AAAAAAAGATTTCCAATCTGCATCAGTAAT	5' untranslated region
LC012.ABI	AAGATTTCCAATCTG	5' untranslated region
LC013.ABI	CAGTGTCCTAGGACAGTCACCCCTTTTTTC	5' coding region
LC014.ABI	GGACAGTCACCCCTT	5' coding region
LC015.ABI	TGTACAAATTGCTGTAGACAGTGTACCAGT	mid coding region
LC016.ABI	GCTGTAGACAGTGTA	mid coding region
LC017.ABI	GTGCGAGCGAGGACCGTCCCGTACCCAACC	3' coding region
LC018.ABI	GGACCGTCCCGTACC	3' coding region
LC019.ABI	TTTAACAGGTGGAATCCATCATTGGTGGTG	5' coding region
LC020.ABI	GGAATCCATCATTGG	5' coding region

Fig. 6


UTC
1759
1757
1764
1756
1754
1753
1752
1751
OLIGO
0
20
40
60
80
% ACETYLATION
PHOSPHOTHIOATE
PHOSPHODIESTER

Fig. 7



	1751	1753	1759	1764	CONTROL
UNTREATED	27	27	27	27	27
0.005uM	23	29	25.1	26.8	26.9
0.05uM	21	9	17.45	14.8	26.8
0.5uM	11	3.2	15.3	6.6	28.1
5.0uM	12	1.9	11	4.8	21.5

UNTREATED 0.005uM 0.05uM 0.5uM 5.0uM

Fig. 8

E2 TRANSACTIVATOR AUG REGION

```
          2595        2605        2615        2625
           *           *           *           *
AGGAGGAGGAUAGUGAAGAGGAUGGAGACAGCAUGCGAACGUUAACAU
           TCACTTCTCCTACCTCTGTCGTACGCTTGC                003
                      TACCTCTGTCGTACGC                   004
           TCACTTCTCCTACCT                               036
           TCACTTCTCCTACCTCTG                            037
           TCACTTCTCCTACCTCTGTCG                         038
        TCCTATCACTTCTCC                                  039
                 TTCTCCTACCTCTGT                         040
                      CCTACCTCTGTCGTA                    041
```

Fig. 9A

E2 TRANSREPRESSOR AUG REGION

```
          3080        3090        3100        3110
           *           *           *           *
ACUGGGCUCUACUACUGCACCAUGGCCGGUGCUGGACGCAUUUACUA
              TGACGTGGTACCGGCCACGACCTGCGTAAA             005
                   TGGTACCGGCCACGA                       006
                ACGTGGTACCGGCCA                          042
             ATGACGTGGTACCGG                             043
          TGATGACGTGGTACC                                044
       GAGATGATGACGTGG                                   045
```

Fig. 9B



Fig. 10



Fig. 11



FIG. 12


60
50
40
30
20
10
0
FOCI
CONTROL
1751
1753
48
49
48
47
48
36
29
22
48
21
11
2
UTC
0.01uM
0.1uM
1.0uM
UTC
0.01uM
0.1uM
1.0uM

Fig. 13



Fig. 14



FIG. 15

E2_First_Methionine
2710
2720
2730
2740
2750
GAT TCA GAG GAC GAG GAA GAT GGA AGC AAT AGC CAA GCG TTT AGA TGC GTG C
CTA AGT CTC CTG CTC CTT CTA CCT TCG TTA TCG GTT CGC AAA TCT ACG CAC G
D S E D E E D G S N S Q A F R C V
E1 ORF
E2 ORF

Fig. 16

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US90/07067

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) [6]

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5): C12Q 1/70, 1/68; C07H 21/04; A61K 48/00; G01N 33/53

U.S. CL.: 536/27; 435/6; 436/81,501; 935/8,78

II. FIELDS SEARCHED

Minimum Documentation Searched [7]

Classification System	Classification Symbols
US	536/27; 435/6,948; 436/81,501; 935/8,78

Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched [8]

Automated Patent System (APS)
Chemical Abstracts Online (CAS)

III. DOCUMENTS CONSIDERED TO BE RELEVANT [9]

Category [10]	Citation of Document, [11] with indication, where appropriate, of the relevant passages [12]	Relevant to Claim No. [13]
Y,P	US, A, 4,908,306 (**LORINCZ**) 13 March 1990, See claims 1-94.	1-14, 43-51
Y	US, A, 4,849,332 (**LORINCZ**) 18 July 1989, See claims 1-94	1-14, 43-51
Y	US, A, 4,849,331 (**LORINCZ**) 18 July 1989, See claims 1-4.	1-14, 43-51
Y	US, A, 4,849,334 (**LORINCZ**) 18 July 1989, See claims 1-4.	1-14, 43-51
Y,E	US, A, 4,983,728 (**HERZOG**) 08 January 1991, See claims 1-17.	1-14, 43-51
Y	US, A, 4,806,463 (**GOODCHILD**) 21 February 1989, See claims 1-12.	1-42
Y	EMBO JOURNAL, Vol. 6, issued 1987, **BOVER ET AL.** "Differential Promoter Utilization By The Bovine Papillomavirus In Transformed Cells And Productively Infected Wort Tissues", See pages 1027-1035.	1-51

* Special categories of cited documents: [10]

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

21 March 1991

Date of Mailing of this International Search Report

15 APR 1991

International Searching Authority

ISA/US

Signature of Authorized Officer

Gary L. Kunz (vsh)

Form PCT/ISA/210 (second sheet) (rev. 11-87)

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y	Nature Vol. 299, issued 07 October 1982 (LONDON). **CHEN ET AL.**, "The Primary Structure and Genetic Organization Of The Bovine Papillomavirus Type 1 Genome", See pages 529-534.	1-51

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE [1]

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers . because they relate to subject matter [2] not required to be searched by this Authority, namely:

2. ☐ Claim numbers . because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out [3], specifically:

3. ☐ Claim numbers_____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING [2]

This International Searching Authority found multiple inventions in this international application as follows:

See attachment to PCT telephone memorandum.

1 ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application. Telephone practice

2 ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3 ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4 ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.